Clinical Trial Detail

NCT ID NCT02627430
Title Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

triple-receptor negative breast cancer

peritoneum cancer

fallopian tube cancer

Advanced Solid Tumor

ovarian cancer

Therapies

Onalespib + Talazoparib

Age Groups: adult

No variant requirements are available.